U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefazolin – Injection products
  1. Development Resources

Cefazolin – Injection products

FDA Identified Breakpoints

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen S I R S I R
Enterobacterales

M-100 standard is recognized

S = Susceptible; I = Intermediate; R = Resistant
Interpretive criteria are based on a dose of 2 g every 8 hr.

Separate susceptibility test interpretive criteria for Enterobacterales for therapy of uncomplicated urinary tract infections are not recognized at this time.

 

Back to Top